VisualSonics Launches Revolutionary Technology to Advance Cancer
TORONTO, June 23, 2011 /CNW/ - Cancer diagnosis and treatment could be
transformed through a breakthrough photoacoustic imaging system
developed by Canada's VisualSonics. Cancer is a leading cause of early
death in Canada, accounting for over 29% of all deaths in Canada1. An innovative new imaging technology known as Vevo® LAZR Photoacoutic
Imaging System by Canada's VisualSonics offers the promise of
dramatically increasing the pace of lifesaving Cancer discoveries where
progress has long been steady but mostly incremental.
"The Vevo LAZR system allows our researchers to see into the processes
that sustain a disease such as cancer," said David A. Jaffray, Ph.D,
Head, Radiation Physics - Ontario Cancer Institute/ Princess Margaret
Hospital, one of the first scientific users of the Vevo LAZR system.
"This imaging system has the potential to transform the way we diagnose
and treat cancer." Jaffray's research focuses on better understanding
some of the factors that affect the way cancer responds to treatment.
Since the response to treatment varies from patient to patient, the
Vevo LAZR technology will help ensure patients get the right treatment,
or what Jaffray describes as "personalized medicine."
Cancer is now known to be a disease caused by changes in a cell's
genetic makeup and its programmed behaviour. The Vevo LAZR platform
enables researchers to study these changes in their earliest stages of
progression by detecting and evaluating cancerous tumor growth in
real-time. For the first time, researchers are able to observe tumor
biology, measure hypoxia (oxygen levels), evaluate changes in blood
flow, and quantify data with unique software solutions in vivo and in real-time. This technology provides researchers with never-before-seen insights into the development of effective therapies for treating cancer.
North American Launch
VisualSonics, a world leader in real-time, high-resolution micro-imaging
systems launched the Vevo LAZR photoacoustic imaging technology in
North America in April, at the annual conference of the American
Association of Cancer Research in Orlando, Florida. Images and data
generated by the Vevo LAZR system were first presented at the World
Molecular Imaging Conference (WMIC) in Kyoto, Japan in September 2010
to a worldwide audience of prestigious organizations and research
European researchers experienced Vevo LAZR technology for the first time
when it was unveiled this month at the 6th annual European Molecular Imaging Meeting in Leiden, The Netherlands.
Advancing Cancer Research
The Vevo LAZR system is designed for use in preclinical research and
could herald major breakthroughs in cancer research in the future when
human applications of the technology are envisioned. The most unique
feature of this pioneering imaging technology is its ability to see
tiny structures at a molecular level such as nuclei inside a living
cell. The Vevo LAZR system uses a laser to shoot pulses of light
through the skin into tissue and cells beneath the surface. The
absorbed laser energy is converted into heat, producing an ultrasonic
emission that is captured and turned into images using a specially
adapted high-frequency ultrasound probe.
Since the launch, there has been a great deal of interest and excitement
in the Vevo LAZR technology from researchers around the world. The Vevo
LAZR system is currently being used at research facilities in Canada,
the U.S. as well as Japan.
"The Vevo LAZR technology offers a crucial opportunity for acceleration
in the study of cancer and its treatment enabling early detection,
early diagnosis and rapid personalized treatment," said Anil Amlani,
VisualSonics' President and CEO. "This technology is allowing
researchers to conduct microscopic level research in a living organism,
non-invasively and in real-time. No other technology can do this." This
leading edge technology will benefit several areas of research
including diabetes, neurosciences, cardiovascular, as well as
developmental and reproductive biology.
"We're thrilled that SonoSite and VisualSonics have teamed up to deliver
new breakthrough imaging technologies," said Kevin M. Goodwin, SonoSite
President and CEO. "VisualSonics is truly at the forefront of imaging
advancements for life-sciences research."
VisualSonics is the world leader in real-time, in vivo, high-resolution micro-imaging systems designed specifically for
preclinical research and is a wholly-owned subsidiary of SonoSite, Inc.
(Nasdaq: Sono). The Company's cutting edge technologies allow
researchers at the world's most prestigious pharmaceutical and
biotechnology companies, hospitals and universities to conduct research
in cardiovascular, cancer, neurobiology and developmental biology
areas. The micro imaging technologies support research applications
that include genetic research, phenotypic studies and drug development.
VisualSonics micro-imaging platforms combine high-resolution, real-time
in vivo imaging at reasonable cost with ease-of-use and quantifiable results.
SonoSite, Inc. is the innovator and world leader in bedside and point-of-care
ultrasound and an industry leader in ultra high-frequency
micro-ultrasound technology and impedance cardiography equipment.
Headquartered near Seattle, the company is represented by fourteen
subsidiaries and a global distribution network in over 100 countries.
SonoSite's small, lightweight systems are expanding the use of
ultrasound across the clinical spectrum by cost-effectively bringing
high-performance ultrasound to the point of patient care.
Forward-looking Information and the Private Litigation Reform Act of
Certain statements in this press release relating to the expected
benefits of the Vevo LAZR Photoacoustics Imaging technology, including
market acceptance of products incorporating Vevo LAZR Photoacoustics
Imaging technology and new market and sales opportunities for SonoSite,
and other statements regarding future results are "forward-looking
statements" for the purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on the opinions and estimates of our management at
the time the statements are made and are subject to risks and
uncertainties that could cause actual results to differ materially from
those expected or implied by the forward-looking statements. These
statements are not guaranties of future performance and are subject to
known and unknown risks and uncertainties and are based on potentially
inaccurate assumptions. Factors that could cause actual results to
differ from the forward-looking statements include: the risk that the
technology will not yield the expected potential benefits, including
the risk that we are unsuccessful in achieving market acceptance of
this technology, and the potential for competitive technologies, as
well as other factors contained in the Item 1A. "Risk Factors" section
of SonoSite, Inc.'s most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission. We caution readers not to place
undue reliance upon these forward-looking statements that speak only as
to the date of this release. We undertake no obligation to publicly
revise any forward-looking statements to reflect new information,
events or circumstances after the date of this release or to reflect
the occurrence of unanticipated even.
1 Canadian Cancer Society: General cancer statistics at a glance; http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/Stats%20at%20a%20glance/General%20cancer%20stats.aspx?sc_lang=en
For further information:
Danna O'Brien, Playbook Communications,
Shailja Tewari, VisualSonics
firstname.lastname@example.org 416-484-5000 x5220